![](https://www.canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaHNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--a715d05398565e02492b14665632b01dc4c42aa2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/Vivace-Website.fw_.png)
Vivace Therapeutics
Vivace Therapeutics develops first in class YAP-TEAD inhibitors for targeted oncology.
Website
vivacetherapeutics.comPartner
Tim ShannonInvestment
Series A
Vivace Therapeutics develops first in class YAP-TEAD inhibitors for targeted oncology.
Series A